Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,32272419,IC50,"The profile of the most optimized inhibitor (36) showed IC50 values of 0.87 and 0.32 nM against FLT3 and FLT3/D835Y, respectively, along with potent inhibition against MV4-11 and FLT3/D835Y expressed MOLM14 cells with a GI50 value of 1.0 and 1.87 nM, respectively.",Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272419/),nM,0.87,16646,DB02052,Indirubin-3'-Monoxime
,32272419,IC50,"The profile of the most optimized inhibitor (36) showed IC50 values of 0.87 and 0.32 nM against FLT3 and FLT3/D835Y, respectively, along with potent inhibition against MV4-11 and FLT3/D835Y expressed MOLM14 cells with a GI50 value of 1.0 and 1.87 nM, respectively.",Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272419/),nM,0.32,16647,DB02052,Indirubin-3'-Monoxime
,32272419,GI50,"The profile of the most optimized inhibitor (36) showed IC50 values of 0.87 and 0.32 nM against FLT3 and FLT3/D835Y, respectively, along with potent inhibition against MV4-11 and FLT3/D835Y expressed MOLM14 cells with a GI50 value of 1.0 and 1.87 nM, respectively.",Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272419/),nM,1.0,16648,DB02052,Indirubin-3'-Monoxime
,32272419,GI50,"The profile of the most optimized inhibitor (36) showed IC50 values of 0.87 and 0.32 nM against FLT3 and FLT3/D835Y, respectively, along with potent inhibition against MV4-11 and FLT3/D835Y expressed MOLM14 cells with a GI50 value of 1.0 and 1.87 nM, respectively.",Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272419/),nM,1.87,16649,DB02052,Indirubin-3'-Monoxime
,32272419,oral bioavailability,"With the high oral bioavailability of 42.6%, compound 36 displayed significant in vivo antitumor activity by oral administration of 20 mg/kg once daily dosing schedule for 21 days in a mouse xenograft model.",Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32272419/),%,42.6,16650,DB02052,Indirubin-3'-Monoxime
,32349415,m/,"The MRM transitions were optimized as m/z 426.2→113.1 for LDD-2614 and m/z 390.2→113.1 for LDD-2633 (internal standard), and the lower limit of quantification (LLOQ) for LDD-2614 was determined as 0.1 ng/mL.",Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32349415/),,426.2,252858,DB02052,Indirubin-3'-Monoxime
,32349415,m/z,"The MRM transitions were optimized as m/z 426.2→113.1 for LDD-2614 and m/z 390.2→113.1 for LDD-2633 (internal standard), and the lower limit of quantification (LLOQ) for LDD-2614 was determined as 0.1 ng/mL.",Development of UHPLC-MS/MS Method for Indirubin-3'-Oxime Derivative as a Novel FLT3 Inhibitor and Pharmacokinetic Study in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32349415/),,390.2,252859,DB02052,Indirubin-3'-Monoxime
